Deliberately less selective than its predecessors, on the logic that a broader grip on the receptor family answers what a narrow one cannot.
Identity
- Class
- Somatostatin analog (cyclic hexapeptide)
- Source
- Synthetic analog of somatostatin
- Receptor
- Somatostatin receptors (SSTR1, 2, 3, and 5)
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Pasireotide binds a wider range of somatostatin receptor subtypes than octreotide — including SSTR1, 2, 3, and 5 — giving it a different activity profile, notably more SSTR5 engagement that underlies its use in conditions octreotide addresses less well.
Reference notes
- Its broader SSTR-subtype coverage is the key distinction from octreotide and lanreotide.
- Greater SSTR5 affinity drives a different clinical profile.
- Illustrates how analog receptor-selectivity engineering changes effects.
Regulatory status
United States · reviewed September 2026- Basis
- Signifor (2012) and Signifor LAR approved for Cushing's disease and acromegaly.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Pasireotide?
- A broader-spectrum somatostatin analog hitting more receptor subtypes. Structurally it is Somatostatin analog (cyclic hexapeptide).
- How does Pasireotide work?
- Pasireotide binds a wider range of somatostatin receptor subtypes than octreotide — including SSTR1, 2, 3, and 5 — giving it a different activity profile, notably more SSTR5 engagement that underlies its use in conditions octreotide addresses less well.
- How strong is the evidence for Pasireotide?
- PeptideHormone grades Pasireotide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of Pasireotide?
- The reported circulating half-life of Pasireotide is ~12 h.
- Is Pasireotide FDA-approved?
- Yes — as of September 2026, Pasireotide is an approved prescription medicine in the United States. Signifor (2012) and Signifor LAR approved for Cushing's disease and acromegaly. Status is US-centric and can change; check the FDA record for the current position.
- Is Pasireotide the same as Signifor?
- Signifor is a brand name of Pasireotide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.
In the literature
Live registry counts · retrieved- Ph 118
- Ph 241
- Ph 310
- Ph 48
Searched as Pasireotide, Signifor. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on Pasireotide, not how it turned out.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Diagnosis and Treatment of Pituitary Adenomas: A Review · JAMA, 2017 · PMID 28170483
- 2.Acromegaly · Nature reviews. Disease primers, 2019 · PMID 30899019
External references
Pasireotide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.